Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 9 results.
User Information
Export Records
  1. 1.   Deciphering the mechanism of potent peptidomimetic inhibitors targeting Plasmepsins: Biochemical and structural insights
  2. Mishra, Vandana; Rathore, Ishan; Arekar, Anagha; Sthanam, Lakshmi Kavitha; Xiao, Huogen; Kiso, Yoshiaki; Sen, Shamik; Patankar, Swati; Gustchina, Alla; Hidaka, Koushi; Wlodawer, Alexander; Yada, Rickey Y; Bhaumik, Prasenjit
  3. FEBS Journal. 2018, Aug; 285(16): 3077-3096.
  1. 2.   Exon Array Analyses across the NCI-60 Reveal Potential Regulation of TOP1 by Transcription Pausing at Guanosine Quartets in the First Intron
  2. Reinhold, W. C.; Mergny, J. L.; Liu, H. F.; Ryan, M.; Pfister, T. D.; Kinders, R.; Parchment, R.; Doroshow, J.; Weinstein, J. N.; Pommier, Y.
  3. Cancer Research. 2010, Mar; 70(6): 2191-2203.
  1. 3.   Monitoring Drug-Induced gamma H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
  2. Wang, L. H.; Pfister, T. D.; Parchment, R. E.; Kummar, S.; Rubinstein, L.; Evrard, Y. A.; Gutierrez, M. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.; Kinders, R. J.
  3. Clinical Cancer Research. 2010, Feb; 16(3): 1073-1084.
  1. 4.   4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl-DNA Phosphodiesterase (Tdp1) Inhibitors
  2. Dexheimer, T. S.; Gediya, L. K.; Stephen, A. G.; Weidlich, I.; Antony, S.; March, C.; Interthal, H.; Nicklaus, M.; Fisher, R. J.; Njar, V. C.; Pommier, Y.
  3. Journal of Medicinal Chemistry. 2009 52(22): 7122-7131.
  1. 5.   Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay
  2. Morrell, A.; Jayaraman, M.; Nagarajan, M.; Fox, B. M.; Meckley, M. R.; Ioanoviciu, A.; Pommier, Y.; Antony, S.; Hollineshead, M.; Cushman, M.
  3. Bioorganic & Medicinal Chemistry Letters. 2006, Aug; 16(16): 4395-4399.
  1. 6.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 7.   A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy
  2. Cragg, G. M.; Newman, D. J.
  3. Journal of Natural Products. 2004 67(2): 232-244.
  1. 8.   Testing of new agents in childhood cancer preclinical models: Meeting summary
  2. Houghton, P. J.; Adamson, P. C.; Blaney, S.; Fine, H. A.; Gorlick, R.; Haber, M.; Helman, L.; Hirschfeld, D.; Hollingshead, M. G.; Israel, M. A.; Lock, R. B.; Maris, J. M.; Merlino, G.; Patterson, W.; Reynolds, C. P.; Shannon, K.; Yu, A.; Yu, J.; Smith, M. A.
  3. Clinical Cancer Research. 2002 8(12): 3646-3657.
  1. 9.   Topotecan and the Treatment of Recurrent Ovarian Cancer - Is There a Role For Granulocyte Colony-Stimulating Factor
  2. Saltz, L.; Janik, J. E.
  3. Seminars in Oncology. 1997 24(1 Suppl 5): S 26-S 30.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel